Chronic Kidney Disease Treatment Market Size, Share and Global Trend By Type of Treatment (Drugs, Dialysis, Transplantation of Kidneys, Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centres (ASCs), Dialysis Centers, Others), and Regional Forecast, 2024-2032

Chronic kidney disease, also known as chronic kidney failure, defined as the gradual loss of kidney function. Kidneys filter wastes and excess fluids from blood, which are then excreted in the urine. When chronic kidney disease reaches an advanced stage, dangerous levels of fluid, electrolytes, and wastes can build up in the human body. In the early stages of chronic kidney disease, have few signs or symptoms. Chronic kidney disease is apparent until your kidney function is significantly impaired. According to the National Kidney Foundation, 10.0% of the population worldwide is affected by chronic kidney disease (CKD), and millions die each year because of less affordable treatment. The critical role of the kidneys in the maintenance of the overall health and the other comorbidities associated with chronic kidney failure is anticipated to contribute to the positive growth of the market.

The rise in the prevalence and incidence of several diseases such as diabetes, hypertension, interstitial nephritis, glomerulonephritis, polycystic kidney disease, and others are the some of the major conditions responsible for the high demand for the kidney disease treatment globally. Additionally, increasing the prevalence of kidney diseases and the rising demand for new techniques for the diagnosis of chronic diseases are some of the major factors driving the growth of the global chronic kidney disease treatment market.

The high cost of treatment and the presence of generic drugs in the market by new players are some of the factors restraining the growth of the global chronic kidney disease treatment market.

Key Players Covered

Some of the major companies that are present in the global chronic kidney disease treatment market are F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., AstraZeneca plc, Pfizer, Inc., Amgen Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., Keryx Biopharmaceuticals, Inc., Allergan plc., FibroGen Inc., Johnson & Johnson, and others.

SEGMENTATION

Among the treatment type, drugs, and dialysis are projected to hold a considerable share of the global chronic kidney disease treatment market due to higher adoption of these treatment options for chronic kidney disease treatment in developed as well as developing countries.

Key Insights

• Regulatory scenario for key countries


• New product launches


• Recent industry developments such as partnerships, mergers, and acquisitions


• Prevalence of chronic kidney disease, by key countries


• Pricing analysis by treatment type

Regional Analysis

Among the regions, North America dominated the global chronic kidney disease treatment market in 2018. According to, Centers for Disease Control and Prevention in 2017, 30 million people or 15% of U.S. adults are estimated to have chronic kidney disease. Asia Pacific is expected to grow at a significant CAGR due to the increasing number of kidney diseases registered, technological advancement in the diagnosis and treatment of the chronic kidney diseases, and initiatives taken by the government about spreading awareness about the kidney diseases symptom as well as treatment in the region. According to, Centers for Disease Control and Prevention in 2017, it is estimated that the number of cases of kidney failure will increase disproportionately in developing countries, such as China and India, where the number of elderly people is increasing, that would result in increasing demand for the chronic kidney disease treatment in the region.

Key Industry Developments

• In June 2019, Akebia Therapeutics launched their program AkebiaCares, an enhanced patient access program for people diagnosed with chronic kidney disease


• In March 2019, Janssen Pharmaceutical submitted the supplemental new drug application to the U.S. FDA for their drug INVOKANA (canagliflozin), for the treatment of chronic kidney disease for patients with Type II diabetes


• In December 2018, AstraZeneca announced that its partner FibroGen Medical Technology Development Co., Ltd. (FibroGen China) received the formal marketing authorisation in China for roxadustat, for the treatment of anemia in patients with chronic kidney disease